Millstone Evans Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Millstone Evans Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.45K	Buy	+15	New	+$6.65K	﹤0.01%	632

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Millstone Evans Group's VRTX Position: Q2 2026 in Review

Millstone Evans Group opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 15 shares worth $7.45K. The stake represents ﹤0.01% of the portfolio and ranks #632 among its holdings.

1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Millstone Evans Group held 15 shares of Vertex Pharmaceuticals worth $7.45K as of Q2 2026.
Vertex Pharmaceuticals was a new Millstone Evans Group position in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Millstone Evans Group's portfolio in Q2 2026, its #632 holding.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.